Faculty Collaboration Database

Dasatinib dose management for the treatment of chronic myeloid leukemia. Cancer 2018 Apr 15;124(8):1660-1672

Date

01/26/2018

Pubmed ID

29370463

Pubmed Central ID

PMC5901015

DOI

10.1002/cncr.31232

Scopus ID

2-s2.0-85045130913 (requires institutional sign-in at Scopus site)   18 Citations

Abstract

Chronic myeloid leukemia (CML) has evolved into a chronic disease that is managed with tyrosine kinase inhibitor therapy. Now that long-term survival has been achieved in patients with CML, the focus of treatment has shifted to dose optimization, with the goal of maintaining response while improving quality of life. In this review, the authors discuss optimizing the dose of the second-generation tyrosine kinase inhibitor dasatinib. Once-daily dosing regimens for dasatinib in the first and later lines of treatment were established through long-term (5-year and 7-year) trials. Recently published data have indicated that further dose optimization may maintain efficacy while minimizing adverse events. Results obtained from dose optimization and discontinuation trials currently in progress will help practitioners determine the best dose and duration of dasatinib for patients with CML, because treatment decisions will be made through continued discussions between physicians and patients. Cancer 2018;124:1660-72. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Author List

Talpaz M, Saglio G, Atallah E, Rousselot P

Author

Ehab L. Atallah MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents
Dasatinib
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Neoplasm
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein Kinase Inhibitors
Quality of Life
Remission Induction
Time Factors
Treatment Failure